Business

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

Financial Post · October 14, 2026 at 9:56 a.m.

PRINCETON, N.J., Oct.

14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the publication of three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) in the Journal of Bone and Mineral Research .

The analysis assessed serum phosphate levels and patient-reported pain, stiffness, and physical function at years 1 and 3 among adults with X-linked hypophosphatemia (XLH) treated with burosumab or oral phosphate and active vitamin D (Pi/D).

Read the full study here .

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

More from Financial Post

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

More in Business

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

William Watson: In new pamphlet, U.K.’s Kemi Badenoch points the (right) way

Pipeline, major projects shows Ottawa’s commitment to Alberta, Smith says